Clinical Trial Update: Strategy for Maintenance of HIV Suppression With Once Daily Integrate Inhibitor+Darunavir/Ritonavir in Children [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update on strategies to maintain HIV suppression in children using an integrase inhibitor plus darunavir/ritonavir; completed phase 2/3 study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Integrate Inhibitor (integrase inhibitor)
• darunavir/ritonavir (darunavir/ritonavir)

Snippet

Sponsor: PENTA Foundation | Conditions: HIV Infection | Phase 2, Phase 3 | Status: COMPLETED